License Issuance Fee. As partial consideration for the license granted hereunder, Licensee shall pay Harvard a non-refundable license fee of [**] U.S. Dollars ($[**]) within [**] days after the date on which Licensee completes a Qualifying Financing (as defined in Section 11.2.2 below).
License Issuance Fee. Within thirty (30) days after the Effective Date, Licensee shall pay Harvard a non-refundable license issuance fee in the amount of [**]. Such license issuance fee shall be creditable against any royalty amounts payable under Section 3.3 below with respect to Products sold in calendar year 2016.
License Issuance Fee. Conditional upon Artelo’s exercise of the Option, as partial consideration for the license granted to Artelo by NEOMED under Section 4.1, within ten (10) business days after the delivery of the Option Exercise Notice by Artelo to NEOMED, Artelo shall pay to NEOMED a license issuance fee of [***]. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
License Issuance Fee. In partial consideration of the rights and licenses granted by Ligand hereunder, Chiva shall pay a one-time, non-refundable and non-creditable license issuance fee of one hundred fifty thousand US Dollars for Predafovir (US$150,000) and three hundred fifty thousand US Dollars ($350,000) for MB07133 to Ligand on or before March 31, 2011.
License Issuance Fee. Licensee agrees to pay Harvard a non-refundable license fee of Ten Thousand U.S. Dollars ($10,000), due and payable within thirty (30) days after the Effective Date.
License Issuance Fee. As partial consideration for the grant to OPIANT of the License, OPIANT shall pay to AEGIS a (i) one-time, nonrefundable and noncreditable license fee of [***] as of the Execution Date; and (ii) one-time, nonrefundable and noncreditable license fee of [***] upon the earlier of the manufacture of the first test development batch for a Product containing naltrexone or July 15, 2017. OPIANT may elect to pay up to 50% of the License Issuance Fee by issuing to AEGIS shares of OPIANT’S common stock subject to the following:
(a) There must be a public market for OPIANT’S shares and OPIANT must be current with all statutory filings;
(b) The shares shall be issued pursuant to Rule 144 of the Securities Act of 1933;
(c) The number of shares to be issued shall be calculated as seventy-five percent (75%) of the average closing price for the previous twenty (20) trading days;
(d) As soon as AEGIS has satisfied the statutory holding period, OPIANT’S legal counsel shall provide a legal opinion so that the shares can be sold in accordance with Rule 144 of the Securities Act of 1933.
License Issuance Fee. In partial consideration of the rights granted by Sigilon to Lilly hereunder, Lilly shall pay to Sigilon a one-time, non-refundable and non-creditable license issuance fee of sixty-two million five hundred thousand U.S. Dollars (U.S. $62,500,000) within [***] days after the Effective Date.
License Issuance Fee. For the rights and privileges granted hereunder, INVITROGEN will pay to P-E a nonrefundable, noncreditable License Issuance fee of * upon execution of the Agreement.
License Issuance Fee. As partial consideration for the license granted hereunder in Harvard’s interest in the Existing Patent Rights, Xxxxxxxx agrees to pay Harvard a non-refundable license fee of [***], due and payable within [***] days after the Effective Date.
